Diasonics ships 2-D array probes
Diasonics has begun shipments of its 2-D array probes followingclearance of the transducers last month by the Food and Drug Administration.The family consists of three probes, in 12-MHz, 7-MHz, and 6-MHzfrequencies, all of which use Diasonics' matched
Diasonics has begun shipments of its 2-D array probes followingclearance of the transducers last month by the Food and Drug Administration.The family consists of three probes, in 12-MHz, 7-MHz, and 6-MHzfrequencies, all of which use Diasonics' matched impedance technology,according to Kenneth Marich, director of marketing communicationsfor the Santa Clara, CA, company.
The 12-MHz probe is a flat linear array for small parts applications,the 7-MHz is a flat linear array for vascular applications, andthe 6-MHz is a curved array for neonatal use, Marich said. Allare available for use on Diasonics Gateway scanners. Diasonicsbelieves that 2-D arrays offer improved spatial and contrast resolution.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.
